natgillin/translations-raw huggingface dataset:
• If you have just started to use this medicine instead of, or as well as, taking corticosteroid tablets, see section 2, Patients who are already taking corticosteroid tablets.
• Če ste pravkar začeli uporabljati to zdravilo namesto kortikosteroidov v obliki tablet ali tablete še vedno jemljete, glejte poglavje 2, Bolniki, ki že jemljejo kortikosteroide v obliki tablet.
If necessary, your doctor may also prescribe corticosteroid tablets and/or, in the case of an infection, an antibiotic.
Zdravnik vam po potrebi lahko predpiše tudi kortikosteroide v obliki tablet in/ali, v primeru okužbe, antibiotik.
Do not store above 50°C.
Shranjujte pri temperaturi do 50°C.
Adolescents who are receiving treatment for a long period of time should have their height checked regularly by their doctor.
Pri mladostnikih, ki dalj časa prejemajo zdravljenje, morajo zdravniki redno preverjati telesno višino.
If your doctor decides to stop treatment or if the inhaler is empty, return it to your pharmacist for safe disposal.
Če se zdravnik odloči prekiniti zdravljenje ali če se inhalator izprazni, ga vrnite farmacevtu, ki ga bo varno odstranil.
The side effects you may experience are:
Neželeni učinki, ki se lahko pojavijo, so:
The following issues were raised concerning this application:
V zvezi s to vlogo so bila izpostavljena naslednja vprašanja:
The expected benefits of your medicine will usually be greater than the risks of suffering any harmful side effects.
Pričakovane koristi jemanja zdravila so običajno večje od tveganj škodljivih neželenih učinkov.
As with most inhaled medicines in pressurised containers, the healing effect of this medicinal product may become smaller when the container is cold.
Kot pri večini zdravil za inhaliranje, ki so v vsebnikih pod tlakom, je lahko zdravilni učinek zdravila manjši, kadar je vsebnik ohlajen.
The treatment period and primary endpoint appear adequate to measure the potential benefit of higher doses of ciclesonide.
Obdobje zdravljenje in primarni pokazatelj sta ustrezna za merjenje možnih koristi večjih odmerkov ciklesonida.
Such a study must comply with the Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Asthma CPMP/EWP/2922/01.
Takšna študija mora biti v skladu z navodilom za klinično raziskovanje zdravil za zdravljenje astme (Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Asthma) CPMP/EWP/2922/01.
Pharmaceutical Form Route of administration
Farmacevtska oblika Pot uporabe zdravila
- If you have any further questions, ask your doctor or pharmacist.
- Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom.
Uncommon side effects (fewer than 1 in every 100 patients treated):
Občasni neželeni učinki (pojavijo se pri manj kot enem od 100 bolnikov):
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF ALVESCO AND ASSOCIATED NAMES (see Annex I)
SPLOŠNI POVZETEK ZNANSTVENE OCENE ZDRAVILA ALVESCO IN Z NJIM POVEZANIH IMEN (glejte Dodatek I)
However, Alvesco delivers the same level of dose from minus 10°C to plus 40°C.
Vendar inhalator zdravila Alvesco dovaja enako stopnjo odmerka pri temperaturi v razponu od minus 10°C do plus 40°C.
When should I use my Alvesco inhaler?
Kdaj moram uporabljati inhalator Alvesco?
Alvesco may affect the normal production of corticosteroids in your body.
Zdravilo Alvesco lahko vpliva na normalno nastajanje kortikosteroidov v telesu.
• An increased dosage of Alvesco may become necessary for a short period of time in patients who suffer a severe worsening of their asthma symptoms.
• Povečan odmerek zdravila Alvesco lahko postane nujen za kratko časovno obdobje pri bolnikih s hudim poslabšanjem simptomov astme.
Your doctor will have spoken to you about how much of your medicine you need to take each day.
Zdravnik se bo z vami pogovoril o tem, kolikšen bo vaš dnevni odmerek zdravila.
If growth rate is slowed, your doctor will adjust your treatment if possible to the lowest dose at which effective control of asthma is maintained.
Če se rast upočasni, bo vaš zdravnik prilagodil vaše zdravljenje na najnižji možni odmerek, ki še zagotavlja učinkoviti nadzor astme.
If you have been taking steroid tablets before or during the use of Alvesco, the risk of side effects from the tablets may continue for a period of time.
Če ste jemali steroide v obliki tablet pred uporabo zdravila Alvesco ali med njo, se lahko tveganje za pojav neželenih učinkov še nekaj časa nadaljuje.
Both ciclesonide doses resulted in comparable FEV1 values at 12 weeks.
Pri obeh odmerkih ciklesonida sta bili vrednosti FEV1 po 12 tednih primerljivi.
After stimulation with 1 and 250 micrograms cosyntropin, no significant changes in plasma cortisol levels were observed versus placebo.
Po stimulaciji z 1 in 250 mikrogrami kozintropina niso opazili pomembnih sprememb v ravni kortizola v plazmi v primerjavi s placebom.
Regular check-ups will also identify any side effects early on and reduce the chances of them worsening.
Ob rednih pregledih se bodo že v začetni fazi pojavili morebitni neželeni učinki, pri čemer se bo zmanjšala možnost poslabšanja.
Do not use your inhaler after the expiry date which is stated on the label and the carton after EXP.
Inhalatorja ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake "Uporabno do".
The risk/benefit analysis of the use of higher doses of ciclesonide in the treatment of severe asthmatics, as the supportive data, interpreted according to the CHMP guidelines, do not allow authorization of regular daily doses in excess of 160 micrograms in the intended populations.
Analiza tveganj in koristi uporabe večjih odmerkov ciklesonida pri zdravljenju hudih astmatikov, glede na to, da podporni podatki, razloženi v skladu s smernicami CHMP, ne omogočajo odobritve rednih dnevnih odmerkov nad 160 mikrogramov pri zdravljenih populacijah.
These rare side effects may include: - reduced rate of growth in adolescents - a thinning of the bones - possible clouding of the lens of the eye (cataracts) causing blurred vision - loss of vision caused by abnormally high pressure in the eye (glaucoma) - moon-shaped face, weight gain in the upper body and thinning arms and legs (Cushingoid features or Cushing syndrome).
Med temi redkimi neželenimi učinki so lahko: - upočasnitev rasti pri mladostnikih - tanjšanje kosti - morebitna zamegljenost leče v očesu (katarakte), ki povzroča zamegljen vid - izguba vida zaradi nenormalno visokega tlaka v očesu (glavkom) - lunast obraz, povečanje telesne teže v zgornjem delu telesa in tanjšanje rok in nog
In addition the CHMP was concerned with introducing the notion of switching from moderate to high dose inhaled corticosteroids to higher doses of Alvesco, as this was not in the original submission.
Poleg tega je CHMP izrazil pomisleke glede uvajanja prehoda z zmernega do visokega odmerka inhaliranih kortikosteroidov na večje odmerke zdravila Alvesco, saj to ni bilo vključeno v prvotno vlogo.
• bad taste, burning, inflammation, irritation, dryness of mouth or throat
• neprijeten okus, pekoč občutek, vnetje, draženje, suha usta ali grlo;
As a conclusion to the evaluation, the CHMP was of the opinion that the proposed wording for Section 4.2 at the end of CMDh would continue to be adequate with the following amendment:
Ob zaključku vrednotenja je CHMP menil, da bo besedilo poglavja 4.2, predlagano ob zaključku postopka v okviru CMDh, še naprej ustrezno ob naslednjem dopolnilu:
The container contains a pressurised liquid.
Vsebnik vsebuje tekočino pod tlakom.
POSSIBLE SIDE EFFECTS
Možni neželeni učinki
Possible side effects
MOŽNI NEŽELENI UČINKI
The CHMP was of the opinion that the MAH had identified a feasible target patient population in the response.
CHMP je menil, da je imetnik dovoljenja za promet z zdravilom v odgovoru navedel primerno ciljno populacijo bolnikov.
Corticosteroid tablets can lead to more side effects than a corticosteroid inhaler such as Alvesco.
Kortikosteroidi v obliki tablet lahko povzročijo več neželenih učinkov kot kortikosteroidi v obliki inhalatorja kot je Alvesco.
• In some patients a dose reduction to 80 micrograms, once daily, may be an adequate dose for maintaining effective control of their asthma.
• Pri nekaterih bolnikih je lahko zmanjšanje odmerka na 80 mikrogramov enkrat dnevno ustrezno za vzdrževanje učinkovitega nadzora astme.
- Your doctor will adjust your dose to the minimum necessary to control your asthma.
- Zdravnik bo odmerek prilagodil do najmanjšega odmerka, ki je potreben, da bo astma nadzorovana.
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT(S), MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, PREDLAGATELJEV, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
The side effects seen with Alvesco are usually mild.
Neželeni učinki, ki se pojavijo pri uporabi zdravila Alvesco, so ponavadi blagi.
• skin rash and/or eczema causing itching and redness.
• kožni izpuščaj in/ali ekcem, ki povzroča srbenje in rdečico.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
- You should start to notice an improvement in your symptoms (wheezing, tight chest and coughing) within 24 hours.
- Simptomi (sopenje, stiskanje v prsnem košu in kašelj) bi se morali v 24 urah opazno izboljšati.
The scientific rationale for difference of opinion regarding the proposed SPC Type II variations' wording of ciclesonides' dose effectiveness on reducing the frequency of exacerbations in severe asthma as drafted in Sections 4.2 and 5.1 by the RMS on the 19th October 2007 following the CMDh hearing.
Znanstvena osnova za razhajajoča se mnenja v zvezi s predlaganim besedilom spremembe tipa II povzetka glavnih značilnosti zdravila glede učinkovitosti odmerka ciklosonidov pri zmanjševanju pogostosti napadov pri hudi astmi, kot ga je v poglavjih 4.2 in 5.1 zasnovala referenčna država članica (RMS) 19. oktobra 2007 po obravnavi v okviru CMDh.
In this leaflet the information is arranged as follows:
Navodilo vsebuje naslednje informacije:
Like all medicines, Alvesco can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Alvesco neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Applicant
Predlagatelj
This can be up to 640 micrograms per day, delivered as 320 micrograms twice daily but no data confirming the additional therapeutic effect after 3 months with these higher doses are available.
Lahko prejmejo do 640 mikrogramov dnevno, razdeljeno na 320 mikrogramov dvakrat dnevno; vendar podatkov, ki bi potrjevali dodaten terapevtski učinek uporabe višjih odmerkov po 3 mesecih, ni na voljo.
Compared to placebo, treatment with ciclesonide 320, 640, and 1280 micrograms/day did not statistically significantly lower the 24-hour time averages of plasma cortisol (AUC(0-24)/24 hours) nor was a dose-dependent effect seen.
V primerjavi s placebom, zdravljenje s 320, 640 in 1280 mikrogrami ciklesonida dnevno ni statistično znatno zmanjšalo 24-urne povprečne koncentracije kortizola v plazmi (AUC(0-24)/24ur) niti ni bil učinek odvisen od odmerka.
Double-blind placebo-controlled trials of 12-weeks duration in adults and adolescents have shown that treatment with ciclesonide resulted in improved lung function as measured by FEV1 and peak expiratory flow, improved asthma symptom control, and decreased need for inhaled beta-2 agonist.
12 tedenske dvojno slepe raziskave pri odraslih in mladostnikih, kontrolirane s placebom, so pokazale, da je zdravljenje s ciklesonidom izboljšalo delovanje pljuč, izmerjeno s FEV1, povečalo največji pretok zraka med izdihom, izboljšalo nadzor nad simptomi astme in zmanjšalo potrebo po inhalaciji beta-2 agonista.
ANNEX IV CONDITIONS OF THE MARKETING AUTHORISATION(S)
DODATEK IV POGOJI DOVOLJENJ(A) ZA PROMET Z ZDRAVILOM
A controlled study compared 24-hour plasma cortisol AUC in 26 adult asthmatic patients following 7 days of treatment.
V kontrolirani raziskavi so po 7 dneh zdravljenja primerjali 24-urno vrednost AUC kortizola v plazmi pri 26 odraslih bolnikih z astmo.
Inhaled ciclesonide treatment was also shown to attenuate the increase in inflammatory cells (total eosinophils) and inflammatory mediators in induced sputum.
Dokazano je bilo tudi, da zdravljenje z inhaliranjem ciklesonida zmanjša širitev celičnega vnetja (skupni eozinofilci) in vnetne mediatorje pri induciranem izpljunku.
The revised Summary of Product Characteristics, labelling and package leaflet are set out in Annex III of the Opinion for Alvesco and associated names (see Annex I).
Popravljen povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so podani v Dodatku III mnenja za zdravilo Alvesco in z njim povezana imena (glejte Dodatek I).
Once orally inhaled, ciclesonide is enzymatically converted in the lungs to the principal metabolite (C21-desmethylpropionyl-ciclesonide) which has a pronounced anti-inflammatory activity and is thus considered as the active metabolite.
Po peroralni inhalaciji se ciklesonid zaradi encimskega delovanja v pljučih pretvori v glavni metabolit (C21-des-metilpropionilciklesonid), ki ima izrazito protivnetno delovanje in se zato šteje za aktivni metabolit.
The CHMP was concerned with the MAH's continued reliance on the results of study MI-140 and its recognized insufficiencies: a short term study of 3 months instead of a minimum of 6 months; the lack of a 320µg/d arm; and the debatable value of improvement in severe exacerbations at the higher 640 dose with no further improvement in lung function.
CHMP je izrazil pomisleke glede stalnega opiranja imetnika dovoljenja za promet z zdravilom na rezultate študije MI-140 in glede njenih prepoznanih pomanjkljivosti: kratkoročna študija v trajanju 3 mesecev namesto najmanj 6 mesecev; odsotnost kraka z odmerkom 320 µg/dan; sporna vrednost izboljšanja pri hudih izbruhih pri večjem 640 µg-odmerku brez nadaljnjega izboljšanja funkcije pljuč.
- The proposed wording for Section 5.1 of the SPC at the end of the CMDh procedure has been amended to include more detail on Study M1 140.
- predlagano besedilo poglavja 5.1 povzetka glavnih značilnosti zdravila je bilo ob zaključku postopka v okviru CMDh dopolnjeno tako, da vključuje več podrobnosti o študiji M1 140;
the CHMP has recommended the granting of the Marketing Authorisation(s) for Alvesco and associated names, with amendments to the relevant sections of the Product Information and with commitments to be fulfilled.
je CHMP priporočil odobritev dovoljenj(a) za promet z zdravilom Avesco in z njim povezanih imen, z dopolnili ustreznih poglavij informacij o zdravilu in obveznostmi, ki jih bo treba izpolniti.
• hoarseness, cough after inhalation, increase in wheezing after inhalation
• hripavost, kašelj po inhaliranju, močnejše sopenje po inhaliranju;
The MAH was asked to explain the different feasible scientific approaches for conducting a well designed study comparing 160 µg, 320 µg and 640 µg in order to clarify the efficacy/safety ratio of 160 µg compared to 320 µg and 640 µg in severe asthmatics.
Imetnik dovoljenja za promet je bil pozvan, da razloži različne primerne znanstvene pristope za izvedbo dobro zasnovane študije, v kateri bi primerjali odmerke 160 µg, 320 µg in 640 µg, da bi tako razjasnili razmerje med učinkovitostjo in varnostjo odmerka 160 µg v primerjavi s 320 µg in 640 µg pri hudih astmatikih.
Ciclesonide exhibits low binding affinity to the glucocorticoid-receptor.
Ciklesonid kaže nizko afiniteto za vezavo na glukokortikoidne receptorje.
Ciclesonide is a glucocorticoid used to treat obstructive airway disease.
Ciklesonid je glukokortikoid, ki se uporablja za zdravljenje obstruktivne bolezni dihal.
In four clinical trials, ciclesonide has been shown to reduce airway hyperresponsivenes to adenosine monophosphate in hyperreactive patients with maximal effect observed at the dose of 640 micrograms.
Štiri klinična preskušanja so pokazala, da ciklesonid zmanjša pretirano odzivnost dihal na adenozin monofosfat pri hiperreaktivnih bolnikih z maksimalnim učinkom opaženim pri odmerku 640 mikrogramov.
Regular check-ups with your doctor will ensure that you are taking the right dose of Alvesco for you.
Zdravnik vam bo z rednimi pregledi zagotovil ustrezen odmerek zdravila Alvesco.
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE LABELLING
DOPOLNILA, KI NAJ SE VKLJUČIJO V ODGOVARJAJOČA POGLAVJA OZNAČEVANJA
The data presented in the responses only reiterated the fact that there is no effective dose ranging data comparing 160, 320 and 640µg/d.
Podatki, ki jih je imetnik dovoljenja za promet z zdravilom predstavil v odgovoru, so zgolj ponovno potrdili, da podatki za opredelitev učinkovitega odmerka, ki bi primerjali odmerke 160, 320 in 640 µg/dan, niso na voljo.
- The MAH has proposed an adequate study which would resolve the outstanding question on the long term use of 320 µg and 640 µg daily.
- imetnik dovoljenja za promet z zdravilom je predlagal ustrezno študijo, s katero bi bilo mogoče podati odgovor na nerešeno vprašanje o dolgoročni uporabi odmerka 320 µg oz. 640 µg na dan;
At the end of the 12 week study period, the results showed a statistically significant difference between the doses of 160 micrograms and 640 micrograms/day ciclesonide with regard to the occurrence of an exacerbation after the first day of the study: 43 patients/339 (= 12.7%) in the 160 micrograms/day group and 23 patients/341 (6.7%) in the 640 micrograms/day group (Hazard ratio=0.526; p= 0.0134).
Po koncu obdobja 12 tedenske raziskave so rezultati pokazali statistično pomembno razliko med odmerkoma 160 mikrogramov in 640 mikrogramov ciklesonida dnevno glede na pojavnost poslabšanja po prvem dnevu raziskave: 43 bolnikov od 339 (12,7%) v skupini z dnevnim odmerkom 160 mikrogramov in 23 bolnikov od 341 (6,7%) v skupini z dnevnim odmerkom 640 mikrogramov (stopnja tveganja=0,526; p=0,0134).
In another trial, pretreatment with ciclesonide for seven days significantly attenuated the early and late phase reactions following inhaled allergen challenge.
Neka druga raziskava je pokazala, da je predhodno sedemdnevno zdravljenje s ciklesonidom po poskusu inhalacije alergena znatno zmanjšalo zgodnjo in pozno fazo reakcij.
The inhaler is an aluminium canister containing 120 doses of either 40 µg, 80 µg or 160 µg ex actuator, corresponding to 50, 100, or 200 µg per puff ex valve.
Inhalator je aluminijast vsebnik, ki vsebuje 120 odmerkov po 40 µg, 80 µg ali 160 µg dostavljenega odmerka, kar ustreza 50, 100 ali 200 µg na vpih merjenega odmerka.
In a clinical trial involving 164 adult male and female asthmatic patients, ciclesonide was given at doses of 320 micrograms or 640 micrograms/day over 12 weeks.
V kliničnem preskušanju, v katerem je sodelovalo 164 odraslih moških in žensk z astmo, so ciklesonid dajali v odmerkih 320 mikrogramov ali 640 mikrogramov na dan 12 tednov.
The CHMP referred to the NfG on the Clinical Investigation of Medicinal Products in the Treatment of Asthma CPMP/EWP/2922/01, and was of the opinion that the MAH had not adequately justified the inclusion of the 320µg/d and 640µg/d ciclesonide.
CHMP je opozoril na navodilo za klinično raziskovanje zdravil za zdravljenje astme (Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Asthma) CPMP/EWP/2922/01 ter izrazil mnenje, da imetnik dovoljenja za promet z zdravilom ni ustrezno utemeljil vključitve odmerkov 320 µg in 640 µg ciklesonida dnevno.
United Kingdom Nycomed GmbH Byk-Gulden-Str. 2
Velika Britanija Nycomed GmbH Byk-Gulden-Str. 2
Additionally, the MAH agreed to amend the wording for Section 5.1 in order to include more detail on Study M1 140, to indicate that there was a statistically significant difference between the doses of 160 micrograms/day and 640 micrograms/day ciclesonide with regards to the occurrence of an exacerbation after the first day of the study.
Imetnik dovoljenja za promet z zdravilom se je strinjal z dopolnitvijo besedila za poglavje 5.1, in sicer, da se vključi več podrobnosti o študiji M1 140 in navede, da je bila prisotna statistično pomembna razlika med odmerkom 160 mikrogramov in 640 mikrogramov ciklesonida na dan glede na izbruh astme po prvem dnevu študije.
Additionally, no study submitted by the MAH showed a significant improvement in FEV1 above 160µg/d in asthmatics.
Poleg tega nobena izmed študij, ki jih je predložil imetnik dovoljenja za promet z zdravilom, ni pokazala bistvenega izboljšanja forsiranega ekspiratornega volumna (FEV1) pri astmatikih pri odmerku nad 160 µg/dan.
The valid labelling is the final version achieved during the Coordination group procedure.
Veljavno označevanje je končna različica pripravljena v skupini za koordiniranje.
Alvesco 40 Inhaler, 80 Inhaler and 160 Inhaler are products containing ciclesonide, delivered in a pressurized metered dose inhaler containing ethanolic hydrofluoroalkane-134A as propellant.
Alvesco 40 v inhalatorju, 80 v inhalatorju in 160 v inhalatorju so zdravila, ki vsebujejo ciklesonid in so na voljo v odmernem inhalatorju pod tlakom, ki vsebuje potisni plin etanolni hidrofluoroalkan-134A.
Before you use Alvesco (This section contains important information for your safety) How to use Alvesco
Kaj je zdravilo Alvesco in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Alvesco (v tem poglavju so pomembne informacije za vašo varnost)
- The proposed wording for Sections 3, 4 and 5 of the Package Leaflet at the end of the CMDh procedure have been amended accordingly.
- predlagano besedilo za poglavja 3, 4 in 5 navodila za uporabo je bilo ob zaključku postopka v okviru CMDh ustrezno dopolnjeno;
- This medicine has been prescribed for you.
- Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS
DOPOLNILA, KI NAJ SE VKLJUČIJO V ODGOVARJAJOČA POGLAVJA POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA
The CHMP considered the MAH's response to support the additional changes to Section 4.2 of the SPC.
CHMP je obravnaval odgovor imetnika dovoljenja za promet z zdravilom v podporo dodatnim spremembam poglavja 4.2 povzetka glavnih značilnosti zdravila.
- The applicant/MAH is requested to commit to obtaining scientific advice in relation to exploring a suitable study design, and execute such study (ies) to provide further information on the use of the higher dose of Alvesco in the control of severe asthma.
- predlagatelj/imetnik dovoljenja za promet z zdravilom je pozvan, da pridobi znanstveni nasvet za določitev primerne oblike študije ter da izvede takšno študijo (ali več študij), ki bodo zagotovile nadaljnje informacije o uporabi večjega odmerka zdravila Alvesco za nadzor hude astme.
Read all of this leaflet carefully before you start using this medicine.
Pred uporabo natančno preberite navodilo!
In a 12-week study of 680 severe asthmatics, previously treated with 500 - 1000 micrograms fluticasone propionate per day or equivalent, 87.3% and 93.3% of patients remained exacerbation-free during treatment with 160 or 640 micrograms of ciclesonide, respectively.
V 12-tedenski raziskavi 680 hudih astmatikov, ki so bili predhodno zdravljeni s 500-1000 mikrogrami flutikazon-propionata na dan ali z enakovrednim odmerkom, je ob zdravljenju s 160 ali 640 mikrogrami ciklesonida ostalo brez poslabšanja bolezni 87,3% in 93,3% bolnikov.
The applicant/MAH is requested to commit to obtaining scientific advice in relation to exploring a suitable study design, and execute such study (ies) to provide further information on the use of the higher dose of Alvesco in the control of severe asthma.
Predlagatelj/imetnik dovoljenja za promet z zdravilom je pozvan, da pridobi znanstven nasvet za določitev primerne oblike študije ter da izvede takšno študijo (ali več študij), ki bodo zagotovile nadaljnje informacije o uporabi večjega odmerka zdravila Alvesco za nadzor hude astme.